Review
InformaticsComputational toxicology in drug development
Informatics
Section snippets
Computational methods applicable for toxicity prediction
In silico techniques for the prediction of toxicological endpoints are extremely appealing because of their expeditious return of results and their inexpensiveness. Moreover, these techniques can be used in a very early phase of drug discovery even before the molecule is synthesized. Numerous commercially available and free web-based programs for toxicity prediction are available; some of them are listed and briefly described in Table 1.
In silico prediction methods that are widely used in the
Application of SAR models in cardiovascular safety pharmacology
Some recent withdrawals of otherwise successful drugs from the market received particular attention owing to their rare induction of potentially life-threatening ventricular tachyarrhythmias of the Torsades de Pointes (TdP) type [37]. In fact most, if not all, of the non-cardiovascular agents associated with a torsadogenic liability prolong the QT-interval by blocking the rapidly activating component of the delayed rectifier potassium current, termed IKr. The ion channel protein is encoded by
Drug bioactivation and hepatotoxicity
Major reasons for drug failure are adverse events in man with some toxicities appearing only during the post-approval period of a drug. Serious adverse drug reactions are believed to be one of the leading causes of death in the United States and are estimated to have occurred in over two million patients in 1994 with more than 100 000 fatalities. Hepatotoxicity has been identified as the major safety concern for discontinuation of clinical trials and either post-approval withdrawal [45] or
In silico screening for drug-induced phospholipidosis
Phospholipidosis describes the intracellular accumulation of various phospholipids reflecting a disorder in phospholipid storage in the lysosomes. Drug-induced phospholipidosis was first reported in 1966 when Greselin [51] observed an increased number of foam cells in the rat lung after the application of a cholesterol metabolism inhibitor. Since then, a number of drug-induced phospholipid disorders have been described in animals and humans for a wide variety of pharmacological compounds like
Predicting non-DNA reactive genotoxic activity of kinase inhibitors in early drug development
Identification of genotoxic liabilities is one of the key functions in preclinical safety assessment of drug discovery. The main reason is to judge any relevant mechanisms leading to mutations as part of the initiating process for carcinogenesis. It is inherent in this area of safety assessment that human data are normally lacking.
Direct-acting genotoxins can be predicted with a very high concordance, as high-quality and comprehensive databases are available for nearly all kinds of genotoxicity
Conclusions and future trends
In general, drug-induced ADRs can be classified in (a) direct-acting mechanisms, which are often triggered by bioactivation of the parent drug to toxic reactive, typically electrophilic metabolites capable of covalent binding to cellular macromolecules and (b) pharmacology-related undesired effects (primary target or cross-reactivities). It has been shown in the present review that computational methods can be successfully applied in early drug development and SARs can be constructed quite
Acknowledgements
The authors thank Dr Manfred Kansy for helpful scientific discussions and Dr Jacqueline Gillis for carefully reviewing the manuscript.
References (73)
Computer systems for the prediction of toxicity: an update
Adv. Drug Deliv. Rev.
(2002)Quantitative structure–activity relationships (QSARs). In toxicology: a historical perspective
THEOCHEM
(2003)In silico prediction of drug safety: despite progress there is abundant room for improvement
Drug Discov. Today: Technol.
(2004)The expanding role of quantitative structure–activity relationships (QSAR) in toxicology
Toxicol. Lett.
(1995)- et al.
A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES Software
Regul. Toxicol. Pharmacol.
(1998) Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices
Regul. Toxicol. Pharmacol.
(2003)Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models
Regul. Toxicol. Pharmacol.
(2007)Validation of a novel molecular orbital approach (COMPACT) for the prospective safety evaluation of chemicals, by comparison with rodent carcinogenicity and the Salmonella mutagenicity data evaluated by the U.s. NCI/NTP
Mut. Res. Env. Mutagen. Relat. Sub.
(1993)Kinase inhibitor recognition by use of a multivariable QSAR model
J. Mol. Graph. Model.
(2006)Acquired QT interval prolongation and HERG: implications for drug discovery and development
Eur. J. Pharmacol.
(2004)